Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

Crystal Structure of Nlrc4 Reveals Its Autoinhibition Mechanism

Structural and Biochemical Basis for Induced Self-Propagation of NLRC4.

Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation

Structural basis for the oligomerization-facilitated NLRP3 activation

Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3

Cryo-EM Structure of the Activated NAIP2/NLRC4 Inflammasome Reveals Nucleated Polymerization

Abstract B134: Cryo-EM Structure of the Activated NAIP2-NLRC4 Inflammasome Reveals Nucleated Polymerization

NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation

Structural Basis of ALC1/CHD1L Autoinhibition and the Mechanism of Activation by the Nucleosome

Structural Biology of NOD-Like Receptors

Crystal structure of the human NLRP9 pyrin domain suggests a distinct mode of inflammasome assembly

Structural and biochemical mechanisms of NLRP1 inhibition by DPP9

Structural basis of the human NAIP/NLRC4 inflammasome assembly and pathogen sensing

Structural basis for specific flagellin recognition by the NLR protein NAIP5

Autoinhibition of UNC5b Revealed by the Cytoplasmic Domain Structure of the Receptor.

Oligomerization-mediated autoinhibition and cofactor binding of a plant NLR

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

Structural Mechanism for NEK7-licensed Activation of NLRP3 Inflammasome

Activation of NLRP3 Inflammasome by Crystalline Structures Via Cell Surface Contact

Rotation and Self-Assembly Driving NLRP3 Activation

Mechanism of NMDA Receptor Inhibition and Activation